Elivaldogene autotemcel

Therapeutic indications

Elivaldogene autotemcel is indicated for:

Early cerebral adrenoleukodystrophy in patients with an ABCD1 genetic mutation

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Elivaldogene autotemcel is indicated for the treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an ABCD1 genetic mutation, and for whom a human leukocyte antigen (HLA)-matched sibling haematopoietic stem cell (HSC) donor is not available.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Elivaldogene autotemcel is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Patients seropositive for human immunodeficiency virus (HIV)

Human immunodeficiency virus infection

Antiretroviral medicinal products

at least one of
Nucleoside and nucleotide reverse transcriptase inhibitors
Antivirals for treatment of HIV infections, combinations

Blood, organ, tissue and cell donation

at least one of
Blood unit collection
Organ retrieval operation
Transplantation

Live vaccines

Live organism vaccines

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2021: SKYSONA Dispersion for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈